<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology</h2>
    <div class="badge">2025-09-08T22:05:00+00:00</div>
    <ul>
      <li>Corner Therapeutics aims to begin clinical trials of its hyperactivator technology by the end of 2027.</li>
<li>Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology WATERTOWN, Mass., September 08, 2025--(BUSINESS WIRE)--Corner Therapeutics, an in vivo T cell modulation and</li>
<li>This innovative approach represents a fundamental shift in how immunotherapies can be optimized for maximum health.</li>
<li>This finding may open the door for the development of a universal flu vaccine that could eliminate the need for annual immunization.</li>
<li>&quot;This research validates a central dogma in immunology, that dendritic cells are the best conduit to robust T cell responses and immunity.</li>
<li>In this study, the scientists at Corner discovered a new class of drugs, called hyperactivators, which engage nature’s T cell engineers in vivo, the dendritic cells.</li>
<li>The study shows that the technology elicits a broadly acting immune response that targets all strains of influenza present in the commercial quadrivalent influenza vaccine Afluria.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology\n• Corner Therapeutics aims to begin clinical trials of its hyperactivator technology by the end of 2027.\n• Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology WATERTOWN, Mass., September 08, 2025--(BUSINESS WIRE)--Corner Therapeutics, an in vivo T cell modulation and\n• This innovative approach represents a fundamental shift in how immunotherapies can be optimized for maximum health.\n• This finding may open the door for the development of a universal flu vaccine that could eliminate the need for annual immunization.\n• &quot;This research validates a central dogma in immunology, that dendritic cells are the best conduit to robust T cell responses and immunity.\n• In this study, the scientists at Corner discovered a new class of drugs, called hyperactivators, which engage nature’s T cell engineers in vivo, the dendritic cells.\n• The study shows that the technology elicits a broadly acting immune response that targets all strains of influenza present in the commercial quadrivalent influenza vaccine Afluria." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/corner-therapeutics-research-opens-path-220500123.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>